Efficacy of High-Dose Atorvastatin Loading Before Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. The STATIN STEMI Trial

JACC: Cardiovascular Interventions

Volumn 3, Issue 3, 2010, Pages 332-339

  Kim, Jung Sun ^a   Kim, Jaedeok ^a   Choi, Donghoon ^a   Lee, Chan Joo ^a   Lee, Sang Hak ^a   Ko, Young Guk ^a   Hong, Myeong Ki ^a   Kim, Byoung Keuk ^b   Oh, Seong Jin ^b   Jeon, Dong Woon ^b   Yang, Joo Young ^b   Cho, Jung Rae ^c   Lee, Nam Ho ^c   Cho, Yun Hyeong ^d   Cho, Deok Kyu ^d   Jang, Yangsoo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Kangnam Sacred Heart Hospital   (South Korea)

^c National Health Insurance Corporation   (South Korea)

^d Hanyang Medical Center   (South Korea)

Author keywords

acute myocardial infarction; percutaneous transluminal coronary angioplasty; statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL;

ADULT; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; KOREA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRROLES; RECURRENCE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77949337131     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.11.021     Document Type: Article

References (25)

1. REPLACE-2 Investigators, Blankenship J.C., Haldis T., Feit F., et al. Angiographic adverse events, creatine kinase-MB elevation, and ischemic end points complicating percutaneous coronary intervention (a REPLACE-2 substudy). Am J Cardiol 97 (2006) 1591-1596
2. Ricciardi M.J., Davidson C.J., Gubernikoff G., et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 145 (2003) 522-528
3. Pasceri V., Patti G., Nusca A., Pristipino C., Richichi G., and Di Sciascio G. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110 (2004) 674-678
4. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49 (2007) 1272-1278
5. Chang S.M., Yazbek N., and Lakkis N.M. Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome. Catheter Cardiovasc Interv 62 (2004) 193-197
6. Di Sciascio G., Patti G., Pasceri V., Gaspardone A., Colonna G., and Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. J Am Coll Cardiol 54 (2009) 558-565
7. Celik T., Kursaklioglu H., Iyisoy A., et al. The effects of prior use of atorvastatin on coronary blood flow after primary percutaneous coronary intervention in patients presenting with acute myocardial infarction. Coron Artery Dis 16 (2005) 321-326
8. Lev E.I., Kornowski R., Vaknin-Assa H., et al. Effect of previous treatment with statins on outcome of patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol 103 (2009) 165-169
9. van't Hof A.W., Liem A., Suryapranata H., Hoorntje J.C., de Boer M.J., and Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97 (1998) 2302-2306
10. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312 (1985) 932-936
11. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
12. van't Hof A.W., Liem A., de Boer M.J., and Zijlstra F. Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial Infarction Study Group. Lancet 350 (1997) 615-619
13. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation 98 (1998) 734-741
14. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
15. MIRACL Study Investigators, Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
16. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 (1995) 1301-1307
17. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
18. Herrmann J., Lerman A., Baumgart D., et al. Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. Circulation 106 (2002) 2180-2183
19. Chan A.W., Bhatt D.L., Chew D.P., et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105 (2002) 691-696
20. Wassmann S., Faul A., Hennen B., Scheller B., Bohm M., and Nickenig G. Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93 (2003) e98-e103
21. Hinoi T., Matsuo S., Tadehara F., Tsujiyama S., and Yamakido M. Acute effect of atorvastatin on coronary circulation measured by transthoracic Doppler echocardiography in patients without coronary artery disease by angiography. Am J Cardiol 96 (2005) 89-91
22. Ray K.K., and Cannon C.P. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?. Am J Cardiol 96 (2005) 54F-60F
23. Briguori C., Visconti G., Focaccio A., et al. Novel Approaches for Preventing or Limiting Events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 54 (2009) 2157-2163
24. Piorkowski M., Fischer S., Stellbaum C., et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?. J Am Coll Cardiol 49 (2007) 1035-1042
25. Bell R.M., and Yellon D.M. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 41 (2003) 508-515